Antabio is a French early-stage drug discovery company that focuses on developing compounds for multi-drug resistant bacterial infections. They have received funding from Wellcome Trust for their two lead programs, which target Metallo Beta-Lactamases inhibitors against E. coli NDM-1 strains and Pseudomonas Biofilms inhibitors in chronic respiratory infections. Their first candidate is a safe and effective inhibitor of bacterial MBLs that will be combined with a carbapenem to treat complicated Gram-negative infections. The second candidate is an inhaled drug that reduces the frequency and severity of Pseudomonas exacerbations by targeting both the virulence and persistence of biofilm-adapted infections. Antabio is seeking additional funds to progress its pipeline and is interested in in-licensing assets focused on Gram-negative antibiotic resistant therapies.